Latest news with #ChristianAngermayer
Cision Canada
30-05-2025
- Business
- Cision Canada
Super Copper Closes Non-Brokered Private Placement with Apeiron Investment Group
VANCOUVER, BC, May 30, 2025 /CNW/ - SUPER COPPER CORP. (CSE: CUPR) (OTCQB: CUPPF) (FSE: N60) (" Super Copper" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of units (the " Units"), raising gross proceeds of $1,000,000 (the "Offering"). Under the Offering, the Company issued 4,000,000 Units at a price of $0.25 per Unit to Apeiron Investment Group Limited (" Apeiron"), a leading global investment firm founded by entrepreneur and investor Christian Angermayer. Each Unit is comprised of one common share and one common share purchase warrant (a " Warrant"). Each Warrant entitles the holder to acquire an additional common share at a price of $0.30 per common share until May 29, 2028. In exchange for Apeiron providing advisory services to the Company, the Company agreed to grant Apeiron an aggregate of 4,000,000 restricted share units (" RSUs") under its equity incentive plan (the " Plan"), of which 3,000,000 RSUs were granted on closing of the Offering and 1,000,000 RSUs will be granted as soon as permitted under the terms of the Plan. To facilitate the granting of the RSUs, an aggregate of 1,200,000 outstanding options were cancelled. Following closing of the Offering and grant of the RSUs, Apeiron holds approximately 10.99% of the issued and outstanding common shares of the Company on an undiluted basis. The Warrants and the RSUs are subject to a restriction on exercise or conversion that prohibits Apeiron from exercising the Warrants or converting the RSUs if the number of common shares to be issued pursuant to such exercise or conversion would exceed, when aggregated with all other common shares of the Company owned by Apeiron, 19.9% of all of the common shares issued and outstanding at such time, unless the Company has obtained shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. In addition if any of the RSUs have not been settled by the date that is three years following the date of grant, and the Company has not obtained shareholder approval for the creation of Aperion as a new "control person" and if settlement of the RSUs in common shares would violate the foregoing restriction, then the Company has agreed to settle such RSUs by paying Apeiron cash equal to the fair market value of the common shares underlying such RSUs. In connection with the Offering, the Company's CEO, Zachary Dolesky and all other directors of the Company entered into voluntary lock-up agreements covering an aggregate of 5,817,360 common shares. Mr. Dolesky has agreed to lock up 5,317,360 common shares for so long as Apeiron maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis). Additionally, subject to Apeiron maintaining a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), the other directors of the Company have agreed to lock up an additional 500,000 common shares for a term of 18 months. Concurrently with the closing of the Offering, Apeiron and the Company entered into an investor rights agreement, that provides, among other things, Apeiron with certain rights in the event it maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), including: (i) the right to participate in equity financings; (ii) top-up rights in the event of dilutive issuances; and (iii) the right to nominate one person to the Company's board of directors. The proceeds raised from the Offering are expected to be used to accelerate the advancement of Super Copper's flagship Cordillera Cobre project in Chile and support broader business expansion initiatives, including targeted acquisitions and for general working capital purposes including marketing and investor relations. The securities underlying the Units and RSUs are subject to a four month hold period, expiring on September 30, 2025 in accordance with applicable Canadian securities laws. Early Warning Disclosure Pursuant to the Offering, on May 29, 2025, Apeiron acquired 4,000,000 Units, at a price of $0.25 per Unit, for total consideration of $1,000,000, as well as 3,000,000 RSUs. Prior to the completion of the Offering, Apeiron did not hold any securities of the Company. Following the completion of the Offering, Apeiron holds 4,000,000 common shares, 4,000,000 Warrants, and 3,000,000 RSUs, representing approximately 10.99% of the Company's issued and outstanding common shares, on an undiluted basis, or approximately 25.35% of the Company's issued and outstanding common shares, on a partially diluted basis, subject, however, to Apeiron being precluded from exercising Warrants or converting RSUs that would result in Apeiron holding more than 19.9% of the then issued and outstanding common shares of the Company, without the Company first obtaining shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. Apeiron acquired the securities of the Company for investment purposes. Apeiron may, depending on market and other conditions, increase or decrease its ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting Apeiron's shareholdings contained in this press release is made pursuant to Multilateral Instrument 62-104 Take-Over Bids and Issuer Bids and a report respecting the above acquisition will be filed with the applicable securities commissions using the System of Electronic Document Analysis and Retrieval (SEDAR+) website at Apeiron's registered office is located at 66 & 67, Beatrice, Amery Street, Sliema SLM1707, Malta. About Apeiron Investment Group Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur Christian Angermayer. At its core, Apeiron is driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. Apeiron prides itself on being a hands-on, reliable and long-term partner – committed to supporting founders and emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. With teams across New York, London, Berlin, Abu Dhabi, and Malta, Apeiron applies a global multi-strategy investment approach, with a primary focus on the US. Apeiron's efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers Apeiron has stakes in currently manage approximately $5 billion in external capital. Through its proprietary balance sheet, Apeiron's direct investment approach encompasses the entire company lifecycle—from incubating and accelerating breakthrough ideas to scaling growth-stage businesses as well as making impactful investments in listed companies. About Super Copper Corp. Super Copper is a mining exploration company focused on the acquisition, exploration and development of copper and precious metal projects. It is currently developing its joint venture in a prospective Chilean copper property located within the copper-rich Venado Formation in the province of Atacama, Northern Chile, a region with world-class infrastructure and the presence of global majors. | The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the " 1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Super Copper Corp. Forward-looking statements include, but are not limited to: the use of proceeds from the Offering; the grant of 1,000,000 RSUs to Apeiron and the terms thereof;; and Apeiron exercising any of its investor rights under the investor rights agreement with the Company. Forward-looking statements reflect management's beliefs, expectations, and estimates as of the date of this news release. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to: exploration results not meeting expectations; geological interpretations proving incorrect; difficulties in obtaining permits or financing for further exploration; changes in commodity prices and market conditions; and general economic and regulatory factors affecting the mining industry. The words "anticipate," "believe," "expect," "intend," "estimate," "plan," "may," "will," "should," "potential," and similar expressions are intended to identify forward-looking statements. Although Super Copper believes that the expectations and assumptions reflected in these statements are reasonable, no assurance can be given that actual results will be consistent with these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investors should carefully review the risks and uncertainties described in the Company's public filings before making investment decisions.
Yahoo
30-05-2025
- Business
- Yahoo
Super Copper Closes Non-Brokered Private Placement with Apeiron Investment Group
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, May 30, 2025 /CNW/ - SUPER COPPER CORP. (CSE: CUPR) (OTCQB: CUPPF) (FSE: N60) ("Super Copper" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of units (the "Units"), raising gross proceeds of $1,000,000 (the "Offering"). Under the Offering, the Company issued 4,000,000 Units at a price of $0.25 per Unit to Apeiron Investment Group Limited ("Apeiron"), a leading global investment firm founded by entrepreneur and investor Christian Angermayer. Each Unit is comprised of one common share and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire an additional common share at a price of $0.30 per common share until May 29, 2028. In exchange for Apeiron providing advisory services to the Company, the Company agreed to grant Apeiron an aggregate of 4,000,000 restricted share units ("RSUs") under its equity incentive plan (the "Plan"), of which 3,000,000 RSUs were granted on closing of the Offering and 1,000,000 RSUs will be granted as soon as permitted under the terms of the Plan. To facilitate the granting of the RSUs, an aggregate of 1,200,000 outstanding options were cancelled. Following closing of the Offering and grant of the RSUs, Apeiron holds approximately 10.99% of the issued and outstanding common shares of the Company on an undiluted basis. The Warrants and the RSUs are subject to a restriction on exercise or conversion that prohibits Apeiron from exercising the Warrants or converting the RSUs if the number of common shares to be issued pursuant to such exercise or conversion would exceed, when aggregated with all other common shares of the Company owned by Apeiron, 19.9% of all of the common shares issued and outstanding at such time, unless the Company has obtained shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. In addition if any of the RSUs have not been settled by the date that is three years following the date of grant, and the Company has not obtained shareholder approval for the creation of Aperion as a new "control person" and if settlement of the RSUs in common shares would violate the foregoing restriction, then the Company has agreed to settle such RSUs by paying Apeiron cash equal to the fair market value of the common shares underlying such RSUs. In connection with the Offering, the Company's CEO, Zachary Dolesky and all other directors of the Company entered into voluntary lock-up agreements covering an aggregate of 5,817,360 common shares. Mr. Dolesky has agreed to lock up 5,317,360 common shares for so long as Apeiron maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis). Additionally, subject to Apeiron maintaining a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), the other directors of the Company have agreed to lock up an additional 500,000 common shares for a term of 18 months. Concurrently with the closing of the Offering, Apeiron and the Company entered into an investor rights agreement, that provides, among other things, Apeiron with certain rights in the event it maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), including: (i) the right to participate in equity financings; (ii) top-up rights in the event of dilutive issuances; and (iii) the right to nominate one person to the Company's board of directors. The proceeds raised from the Offering are expected to be used to accelerate the advancement of Super Copper's flagship Cordillera Cobre project in Chile and support broader business expansion initiatives, including targeted acquisitions and for general working capital purposes including marketing and investor relations. The securities underlying the Units and RSUs are subject to a four month hold period, expiring on September 30, 2025 in accordance with applicable Canadian securities laws. Early Warning Disclosure Pursuant to the Offering, on May 29, 2025, Apeiron acquired 4,000,000 Units, at a price of $0.25 per Unit, for total consideration of $1,000,000, as well as 3,000,000 RSUs. Prior to the completion of the Offering, Apeiron did not hold any securities of the Company. Following the completion of the Offering, Apeiron holds 4,000,000 common shares, 4,000,000 Warrants, and 3,000,000 RSUs, representing approximately 10.99% of the Company's issued and outstanding common shares, on an undiluted basis, or approximately 25.35% of the Company's issued and outstanding common shares, on a partially diluted basis, subject, however, to Apeiron being precluded from exercising Warrants or converting RSUs that would result in Apeiron holding more than 19.9% of the then issued and outstanding common shares of the Company, without the Company first obtaining shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. Apeiron acquired the securities of the Company for investment purposes. Apeiron may, depending on market and other conditions, increase or decrease its ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting Apeiron's shareholdings contained in this press release is made pursuant to Multilateral Instrument 62-104 Take-Over Bids and Issuer Bids and a report respecting the above acquisition will be filed with the applicable securities commissions using the System of Electronic Document Analysis and Retrieval (SEDAR+) website at Apeiron's registered office is located at 66 & 67, Beatrice, Amery Street, Sliema SLM1707, Malta. About Apeiron Investment Group Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur Christian Angermayer. At its core, Apeiron is driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. Apeiron prides itself on being a hands-on, reliable and long-term partner – committed to supporting founders and emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. With teams across New York, London, Berlin, Abu Dhabi, and Malta, Apeiron applies a global multi-strategy investment approach, with a primary focus on the US. Apeiron's efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers Apeiron has stakes in currently manage approximately $5 billion in external capital. Through its proprietary balance sheet, Apeiron's direct investment approach encompasses the entire company lifecycle—from incubating and accelerating breakthrough ideas to scaling growth-stage businesses as well as making impactful investments in listed companies. About Super Copper Corp. Super Copper is a mining exploration company focused on the acquisition, exploration and development of copper and precious metal projects. It is currently developing its joint venture in a prospective Chilean copper property located within the copper-rich Venado Formation in the province of Atacama, Northern Chile, a region with world-class infrastructure and the presence of global majors. | The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Super Copper Corp. Forward-looking statements include, but are not limited to: the use of proceeds from the Offering; the grant of 1,000,000 RSUs to Apeiron and the terms thereof;; and Apeiron exercising any of its investor rights under the investor rights agreement with the Company. Forward-looking statements reflect management's beliefs, expectations, and estimates as of the date of this news release. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to: exploration results not meeting expectations; geological interpretations proving incorrect; difficulties in obtaining permits or financing for further exploration; changes in commodity prices and market conditions; and general economic and regulatory factors affecting the mining industry. The words "anticipate," "believe," "expect," "intend," "estimate," "plan," "may," "will," "should," "potential," and similar expressions are intended to identify forward-looking statements. Although Super Copper believes that the expectations and assumptions reflected in these statements are reasonable, no assurance can be given that actual results will be consistent with these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investors should carefully review the risks and uncertainties described in the Company's public filings before making investment decisions. SOURCE Super Copper Corp. View original content to download multimedia: Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
A German billionaire cofounded the steroid Olympics. Now he's betting on blockchain-powered uranium
The German billionaire Christian Angermayer covers his Manhattan penthouse with symbols of his favorite investments. On one wall is a graffiti print of the Bitcoin crest overlaying U.S. dollars; next to it is a painting of magic mushrooms; and beneath that, an ancient trilobite from the Cambrian period. Perhaps best known for cofounding a steroid-enhanced version of the Olympics backed by Peter Thiel, Angermayer has made his fortune betting on sectors well outside the mainstream economy, such as crypto, psychedelics, and fossils. Last week, in an interview with Fortune from his apartment in the shadow of the Queensboro Bridge, he shared details of his latest passion project: tokenized uranium. Investors are no strangers to commodities as an asset class: gold, of course, is a long-time safe haven, and oil has a slew of exchange-traded products available to traders. But uranium, in no small part due to its key role in nuclear weapon-making, remains an underdeveloped and essentially out-of-reach market, even as demand skyrockets. Just last week, the stocks for advanced reactor companies and uranium miners jumped on a report that President Trump would sign orders to speed the construction of nuclear facilities. For his part, Angermayer is betting on Uranium Digital, a startup founded by the former hedge fund manager Alex Dolesky, which is building a blockchain-based trading platform for uranium available to both retail and institutional customers. Angermayer is investing an undisclosed amount in the company as well as joining as a strategic advisor. Angermayer says that he was searching for an investment in natural resources based on his conviction that AI development would demand new energy sources, like nuclear power. 'Nuclear, and hence uranium, is a very infrastructure way to bet on the AI boom,' he tells Fortune. It just so happened that he found Uranium Digital, a startup building in his other preferred sector of crypto. 'That's how I function,' he continues. 'I always have my big ideas…But I very much believe that's the spiritual, psychedelic side, that you then meet the right people at the right time.' Angermayer started his career as a biotech entrepreneur, cofounding the firm Ribopharma, which merged with a pharmaceutical company in 2003 and made Angermayer millions. He later founded an investment firm, Apeiron, which now has more than $2.5 billion of assets under management, much of it Angermayer's. Apeiron has a diverse portfolio of investments, from Hollywood blockbusters to pioneering manufacturers of psilocybin, the active chemical in magic mushrooms. But Angermayer has become increasingly involved in crypto in recent years, such as helping the renegade stablecoin issuer Tether build out its own portfolio of investments, including in a brain implant company and data center operator. Angermayer says that he first heard of Uranium Digital from two of the startup's first backers: the crypto venture firm Framework and the family office of the former head of coal trading at the commodities giant Glencore. Financial markets for commodities like oil and coal serve as speculative instruments for traders, but they also serve an essential function for firms operating in the space, allowing them to hedge against price swings through derivatives like futures. The pitch for Uranium Digital, according to Dolesky, is that financial markets for crude oil didn't emerge until the 1980s, natural gas in the 1990s, and coal in the mid-2000s. They go from opaque markets driven by over-the-counter trades, meaning little price transparency, to having a full financial architecture system around them. 'That's effectively what we're doing [for uranium],' Dolesky says. Because of the security concerns around uranium, the only way to gain exposure to the element is to buy it through facilities called converters, which hold a powdered form of uranium called yellowcake. That means that the process is highly controlled and slow, with little price transparency. Moreover, traders can only buy and sell, as opposed to building out other types of financial instruments. 'There's no way to express a spectrum of trades,' Dolesky tells Fortune. So why crypto? By tokenizing uranium through the Solana blockchain, the startup can create digital exposure to the element, offering traders near-instant, low-fee trading. In this sense, uranium on the blockchain is akin to dollar-backed stablecoins like Tether. At the same time, most users would not be converting between the digital version of uranium and uranium itself, which would require physical settlement and is restricted to the vast majority of traders. Instead, they will trade the tokenized form, with physical holders able to mint more through a complex system of arbitrage that maintains the price. That connects the retail market, which can't trade physical uranium, with the institutional market, leading to price discovery that would be otherwise impossible. Tokenization has become one of the hottest buzzwords in crypto, with venture firms piling into stablecoin startups and traditional financial institutions like BlackRock exploring blockchain versions of money market funds. Still, most emerging products are at pilot phases or constrained to crypto-native firms. Angermayer says uranium could emerge as a tangible example of blockchain's utility. 'I get most excited when something has a real impact on the real world,' he tells Fortune. Uranium Digital is set to launch in the fall with just spot trading at first, but Angermayer says that his main role as advisor is helping introduce the startup to the world of hedge funds and investment managers that they hope will adopt uranium as a new asset class. That, he and Dolesky argue, will help create hedging instruments, which in turn will benefit companies building in the space. 'This will be another very high-profile example of why crypto really makes sense from a natural strategic [perspective],' Angermayer tells Fortune. He says that he's considering tokenizing another of his favorite investments: dinosaur fossils. He even has a team of paleontologists on archeological digs to discover new ones. 'I'm still thinking about it,' he tells Fortune. 'The question is, how big is the market, and how much time do I have?' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
23-05-2025
- Mint
Dreams of improving the human race are no longer science fiction
IT WAS AFTER tripping on hallucinogenic mushrooms that Christian Angermayer realised he had a personal mission to help the human race improve itself. Having passed through the 'gateway to God" opened by psychedelic drugs, the German tech billionaire wanted to usher the rest of humanity in the same direction. Nowadays his investment fund not only champions the use of such drugs as a treatment for mental-health problems, but is also 'pushing the boundaries for human enhancement overall", meaning treatments to make people stronger, smarter and longer-lived. He has also donated to a $101m prize-pot for scientific breakthroughs that slow ageing and is helping to found a competition called the Enhanced Games, in which athletes can earn $1m for breaking world records using the sorts of doping that would normally disqualify them. Some may consider all this quixotic, but Mr Angermayer is far from the only believer. Human enhancement, from wearable devices that monitor health to neural implants intended to overcome paralysis, is already a $125bn industry, according to imarc, a consultancy, and is growing by more than 10% a year. Firms seeking to increase longevity, just one element of enhancement, attracted almost $5bn in venture capital in the first half of last year. Tech luminaries such as Peter Thiel, co-founder of both PayPal and Palantir, and Sam Altman, the boss of OpenAI, are pouring money into the idea that the human body can be improved. It is not just the vision of a future in which ageing is held at bay and Olympic feats of strength, speed or endurance are commonplace that is exciting investors. They are also energised by the sense that America's current leaders are open to this sort of techno-utopianism and may help foster it. Last month Donald Trump Jr, the eldest son and namesake of America's president, joined Messrs Angermayer and Thiel as an investor in the Enhanced Games. The competition, the younger Mr Trump explained, embodies 'excellence, innovation and American dominance on the world stage—something the MAGA movement is all about". Could the combination of enthusiastic investors and official encouragement pave the way for treatments that redefine the capacity of the human mind and body? Unremarkable or unhinged? People have always sought to transcend the limits imposed by biology: clothes and glasses, not to mention pacemakers and plastic surgery, are all forms of enhancement. Yet the idea of making humanity better stirs memories of eugenics and fears of snake oil. Evangelists for the industry can sound a little mad. Elon Musk, who as well as better-known companies like Tesla has also founded a brain-implant firm called Neuralink, talks about giving people 'superpowers". Bryan Johnson, a 47-year-old tech billionaire, thinks his special health regime may allow him to live for ever. Such talk brushes aside umpteen scientific uncertainties, regulatory hurdles and moral quandaries. But gung-ho enhancers are nonetheless embracing three broad categories of treatments: supplements, gene therapies and neural implants. Health supplements are an industry in themselves, with annual sales of $485bn. In addition, enhancers also use some prescription medicines in ways their manufacturers do not recommend. Herbal extracts such as ginseng, ginkgo and lion's mane (a type of mushroom) are taken to sharpen the mind, as is Adderall, a hyperactivity drug containing amphetamines beloved by sleep-deprived students. Nicotinamide mononucleotide, spermidine, creatine phosphate and, for men, testosterone are all used in the hope of delaying ageing or improving mental or physical prowess. Of mice, not men There is usually some kind of scientific theory behind these sorts of treatments, but typically not the stringent evidence required to win approval for a prescription drug. The chemical concerned may have yielded positive results in research on animals (often mice), but may not have been tested on people. Or it may be intended to treat specific conditions in people, but has not been evaluated for the purpose to which enhancers are putting it. Take, for instance, testosterone, which is routinely prescribed to boost energy and libido and lower anxiety in men whose bodies are not producing enough of it. Robert Kennedy, America's new health secretary, takes testosterone not to overcome a deficiency, but as part of an 'anti-ageing protocol". The hormone has not been tested for this purpose in clinical trials, so it is hard to say whether it will have the effects Mr Kennedy is hoping for—or whether using it in this way might be risky or harmful. The lack of data is no accident. Medical research has, to a very large extent, focused on treating debilitating afflictions, rather than on improving the capabilities of people who are already healthy. Regulators have developed systems to test whether drugs prevent or alleviate known ailments, but these are typically not well suited to assess whether a treatment has a positive effect on those who are already well. Since such enhancements might be considered less urgent, it is anyway less clear how risks and rewards should be balanced. What is more, naturally occurring substances cannot be patented, so there is little incentive for pharmaceutical firms to pour money into research on their effects. That leaves people like Mr Johnson conducting research on themselves. He describes himself as a 'rejuvenation athlete" and spends $2m a year on a regimen that is supervised by a team of scientists. Every day he gets up at about 5am, takes 100 pills (a mix of supplements and prescription medicine), exercises for an hour or more and follows a calorie-controlled vegan diet. He does not eat after 11am and goes to bed by 8.30pm. He sleeps alone, for better rest. And that is the more conventional part of Mr Johnson's health experiments. He recently said he has replaced all his plasma (the liquid part of blood) with a solution of a protein called albumin. He has received a blood transfusion from his son after research in mice had suggested it may have a rejuvenating effect. His intention is to minimise the biological indications of ageing, although that is difficult, since there is no scientific consensus on what they are. He, for instance, seems to set great store by the quantity and duration of his night-time erections, which is not a widely accepted metric. Charles Brenner, a biochemist at the City of Hope, an American medical-research centre, has suggested that Mr Johnson's 'polypharmacy" is likely to be harmful and dismissed his claimed immortality as 'delusional". Without proper clinical trials of his various treatments, it is impossible to judge with any certainty. That is why the world of enhancement is excited about a study called TAME, which is the first clinical trial that targets ageing specifically to be approved by America's Food and Drug Administration (FDA). TAME will test whether metformin, a drug to treat diabetes, can also prolong human lifespans. Since it would be impractical to run a trial over 80 or 90 years, TAME will measure the onset of age-related ailments such as cancer and dementia over a shorter period as a proxy for longevity. In time, the FDA may come to accept other indicators of ageing as the basis for further trials, although agreeing on the format of TAME took years. Another type of treatment championed by enhancers is gene therapy, whereby new genetic material is introduced to the body to alter the way it functions. George Church, a geneticist at Harvard University, argues that humans are reaching the limits of improvements in physical and mental performance that can be achieved through diet and exercise. Further gains, he says, will require advanced technologies such as gene editing. At any rate, improvements in various Olympic records have slowed in recent years (see chart). Whether related to the body's limits or to more stringent anti-doping controls, the slowdown tends to support enhancers' arguments. Existing gene therapies that achieve various medical ends, such as boosting the production of red blood cells for anaemics, or strengthening muscles for those with a wasting disease, are also of interest to enhancers. Doping agencies are worried that athletes will use such treatments, which are hard to detect, in competitive sport. As early as 2006 a German trainer reportedly tried to get hold of an experimental gene therapy called Repoxygen, although there is no evidence that he was successful. Dr Church is a co-founder of a firm called Rejuvenate Bio, which is exploring gene therapy to tackle age-related diseases. In a paper last year in Cellular Reprogramming, a scientific journal, it reported introducing genes into mice to get them to produce proteins called Yamanaka factors that prompt cells to revert to a more youthful state. The animals lived far longer than normal and age-related changes in their DNA diminished. The firm aims to reproduce this effect in humans. Only one genetic enhancement (as opposed to gene therapies for conventional medical purposes) is known to be publicly available. A firm called Minicircle has developed a method to introduce new genes into the body using loops of bacterial DNA called plasmids. It has harnessed this technique to induce the body to produce more follistatin, a hormone that, among other functions, stimulates muscle growth. As usual, most of the underlying research was conducted on mice. Mr Johnson, the immortal tech mogul, received Minicircle's follistatin therapy last year at a clinic on Roatán Island, off the coast of Honduras. The intention, as well as bulking up, was to delay the onset of ageing and even lengthen the ends of chromosomes, which may be an indicator of longevity. The location of the clinic, in the semi-autonomous town of Próspera, was no accident. It is part of a special economic zone with less onerous regulation than the rest of Honduras. It has become known for allowing medical procedures that might not be permitted in other jurisdictions. The private firm that runs the city includes among its backers Mr Altman, Mr Thiel and Marc Andreessen, a celebrated venture capitalist. Mr Altman has also invested in Minicircle. The government of Honduras, however, is trying to rescind Próspera's special status. A third form of treatment championed by enhancers is brain-computer interfaces (BCIs). These can collect and analyse signals from the brain or send signals to it. They can be headsets or invasive implants, inserted into the brain itself. Although a new technology, they have already been used to achieve surprisingly sophisticated results. Scientists have been able to decode activity in the area of the brain that processes visual information to work out what kind of images people are looking at, and even reconstruct those images in some cases. An implant developed by Mr Musk's firm, Neuralink, has allowed a paraplegic to operate a computer with his thoughts. Mr Musk says that it should soon be possible for brain implants to allow disabled patients to move artificial limbs as well. Neuralink is also developing an implant to restore sight to the blind, although it has not yet started human trials. In the long run, however, Mr Musk wants not just to overcome disabilities, but to increase patients' mental powers. He hopes to use BCIs to connect human brains to artificial intelligence, massively augmenting reasoning capacity and knowledge. Investors seem enthusiastic about this vision. Neuralink, which is privately held, has secured several rounds of funding, including one in 2023 led by Mr Thiel's investment fund. Messrs Angermayer and Thiel have also invested in another BCI firm, Blackrock Neurotech. A third, Synchron, counts Jeff Bezos, the founder of Amazon, and Bill Gates, the founder of Microsoft, among its backers. Meanwhile, several wearable BCIs are already on the market. One, made by Flow Neuroscience, uses electrodes attached to the scalp to send a small electrical charge to specific areas of the brain. It is being tested by Britain's National Health Service to treat depression. Other startups hope to tackle different neurological or psychological disorders in a similar way. But in addition to treating conventional ailments, wearable BCIs, too, are intended to enhance. Some devices promise to help users become calmer, more focused and remember more. Another claims to 'elevate your performance" by increasing alertness. There are hopes that BCIs of this sort could detect distraction or fatigue and thus improve workers' performance. The jurisdiction where BCIs are being developed most eagerly is China, where multiple trials are under way involving monkeys and humans. Chinese scientists recently claimed to have developed the world's first non-invasive two-way BCI, allowing a drone and human pilot to communicate with one another. The government has also issued various regulations to hasten the adoption of BCIs. BCIs raise all manner of ethical and legal concerns. If the technology gets sophisticated enough, ensuring privacy and preventing subtle forms of mind control will become urgent and difficult. Regulators will naturally be cautious. But some entrepreneurs hope that the American authorities, at least, will soon be taking a more permissive approach to enhancement in general. Mr Kennedy, after all, is happy to break with medical orthodoxy and has personally embraced some supposed forms of enhancement. He has complained in the past that the FDA is suppressing research into stem-cell therapies. President Trump has nominated Jim O'Neill, a long-term lieutenant of Mr Thiel and a longevity enthusiast, as one of Mr Kennedy's deputies. He, too, has criticised the FDA as unduly cautious in licensing experimental treatments. Aron D'Souza, the head of the Enhanced Games, thinks America's new leadership will unleash 'a technological revolution". 'There's big moves in play," he says. 'The FDA is a great organisation, but ultimately, there are many things and compounds outside of the purview of the current rules, because it's not designed for this rule set." He understands that Mr Trump's administration is already considering loosening regulations around the use of anabolic steroids, for instance, making life easier for bodybuilders. Mr Angermayer, too, insists that the American authorities understand the need to 'change the framework" around the development of new medicines, particularly those targeting longevity, to allow greater scope for enhancement. That, in turn, would spur investment in research and thus hasten the development of new therapies. As exciting as that prospect is to advocates of enhancement, the general public may not be so enthusiastic. A study conducted in 2018 found that the overwhelming majority of Americans approved of treatments that could restore normal physical functions to people who lacked or had lost them, such as the blind and paraplegics. But only a minority endorsed the idea of developing enhancements to human abilities beyond the typical range. Whether this reflects only a fear of the unknown, which will melt away as the potential of enhancement becomes clear, or a more deep-seated unease about tinkering with nature, is hard to say. Other intrusive technologies, such as mobile phones, have been greeted with scepticism at first only to be almost universally embraced as their benefits become apparent. Flaws begone! Proponents of enhancement, at any rate, are optimistic. Mr D'Souza was among the participants at a recent conference in Britain at which enhancement was heralded as both a right and a moral imperative. As he puts it, 'We have the ability to overcome the weakness of our feeble biological forms and become something more." The Enhanced Games, he says, will 'redefine what ageing is about". He wants them to be a popular spectacle and to receive lots of attention. That might help normalise and popularise the idea of enhancement. 'I believe in superhumanity," he declares. The rest of us will soon have the chance to decide if we do, too.
Yahoo
22-05-2025
- Business
- Yahoo
Super Copper Announces Strategic Investment from Apeiron Investment Group
Apeiron Investment Group is the investment firm of renowned investor and entrepreneur Christian Angermayer. Investment strengthens Super Copper's balance sheet with financing consisting of $1 million worth of units. CEO and Directors to sign voluntary lock-up agreements for over 7 million securities to ensure long-term alignment. Funding to increase exploration at Super Copper's flagship Chile property and advance strategic expansion globally, including acquisition initiatives. /THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, May 22, 2025 /CNW/ - SUPER COPPER CORP. (CSE: CUPR) (OTCQB: CUPPF) (FSE: N60) ("Super Copper" or the "Company"), is pleased to announce it has secured a strategic investment from Apeiron Investment Group Limited ("Apeiron"), a leading global investment firm founded by entrepreneur and investor Christian Angermayer. Apeiron has agreed to purchase, through a non-brokered private placement, 4,000,000 units of the Company ("Units"), at a price of $0.25 per Unit, for gross proceeds of $1,000,000 (the "Financing"). Each Unit will be comprised of one common share and one warrant to purchase an additional common share at $0.30 for a 36-month period. Christian Angermayer, Founder of Apeiron Investment Group, stated: "Copper is fundamental to industrial manufacturing, national defense, and critical infrastructure—especially as we enter a new era of accelerated growth driven by AI. We see Super Copper as a pristine platform with excellent potential in the global mining industry. Their Cordillera Cobre project combines strong grades and scale in a premier mining jurisdiction, while the Company's vision for strategic growth through global acquisitions is compelling. Apeiron is enthusiastic about supporting the Super Copper leadership team as they build this innovative copper exploration platform, and we see this investment as just the first step in our long-term partnership. We are proud to support their next phase of growth to unlock the full potential of their vision." Zachary Dolesky, CEO of Super Copper, stated: "This strategic investment from Christian Angermayer's Apeiron Investment Group marks a key moment for Super Copper. With their support, we are accelerating exploration at Cordillera Cobre, while actively pursuing strategic acquisition opportunities to scale our operations globally. Following the financing, Super Copper will remain well-positioned with a strengthened balance sheet, no long-term debt, and approximately 36 million shares outstanding. We are energized and ready to execute on our ambitious vision." Voluntary Management Lock-Up Agreements In connection with the Financing, Super Copper CEO Zachary Dolesky and all other directors and officers of the Company will enter into voluntary lock-up agreements covering an aggregate of approximately 7 million common shares and options. Mr. Dolesky has agreed to lock up 5,317,360 common shares for so long as Apeiron maintains a minimum ownership stake of 10.0% in the Company (on a partially diluted basis). In parallel, subject to Apeiron maintaining a minimum ownership stake of 10.0% in the Company (on a partially diluted basis), all other directors and officers have agreed to lock up an additional 1,725,000 common shares and options for a term of 18 months. These lock-ups reflect alignment between management and shareholders, demonstrate long-term conviction in the Company's growth strategy, and reinforce the stability of the Company's capital structure as it enters its next phase of development. Financing Terms It is expected that Apeiron will hold approximately 10.99% of the issued and outstanding common shares of the Company on completion of the Financing on an undiluted basis. In addition, in exchange for Apeiron providing advisory services to the Company, the Company will grant Apeiron an aggregate of 4,000,000 restricted share units ("RSUs") under its 2024 equity incentive plan (the "Plan"), of which 3,000,000 RSUs will be granted on closing and 1,000,000 RSUs will be granted as soon as permitted under the terms of the Plan and be subject to availability under the Plan. To facilitate the granting of the RSUs, certain option holders have agreed to cancel 1,100,000 outstanding options. The warrants underlying the Units issuable to Apeiron pursuant to the Financing, and the RSUs, will be subject to a restriction on exercise or conversion that prohibits Aperion from exercising the warrants or converting the RSUs if the number of common shares to be issued pursuant to such exercise or conversion would exceed, when aggregated with all other common shares of the Company owned by Apeiron, 19.9% of all of the common shares issued and outstanding at such time, unless the Company has obtained shareholder approval for the creation of a new 'control person', in accordance with the policies of the Canadian Securities Exchange. Concurrently with the closing of the Financing, Apeiron and the Company will enter into an investor rights agreement, that provides, among other things, Apeiron with certain rights in the event it maintains minimum ownership thresholds in the Company, including: (i) the right to participate in equity financings; (ii) top-up rights in the event of dilutive issuances; and (iii) the right (but not the obligation) to nominate one person to the Company's Board of Directors. The Company expects to use the proceeds of the Financing to accelerate the advancement of Super Copper's flagship Cordillera Cobre project in Chile and support broader business expansion initiatives, including targeted acquisitions and for general working capital purposes including marketing and investor relations. The Financing is expected to close on or about May 29, 2025, and the Company does not intend to expand the Financing beyond Apeiron's investment. The securities underlying the Units and RSUs will be subject to a statutory four-month hold period in accordance with applicable Canadian securities laws. Flagship Project: Cordillera Cobre Exploration Program Progress continues at the Cordillera Cobre project, where recent exploration samples confirmed grades of up to 10.3% copper and 296 g/t silver (1). This preliminary sampling has identified widespread copper mineralization, reinforcing the project's potential for a copper system. Cordillera Cobre is located approximately 43 km northeast of Copiapó, Chile — a region with world-class infrastructure and the presence of global majors. The Company is developing its Phase 2 work program and will provide a subsequent update. About Apeiron Investment Group Apeiron Investment Group is a discretionary investment firm founded and owned by serial entrepreneur Christian Angermayer. At its core, Apeiron is driven by a bold optimism for a future where technology empowers people to live longer, healthier, and more fulfilling lives. Apeiron prides itself on being a hands-on, reliable and long-term partner – committed to supporting founders and emerging asset managers in pushing the boundaries of imagination and shaping the future we aspire to live in. With teams across New York, London, Berlin, Abu Dhabi, and Malta, Apeiron applies a global multi-strategy investment approach, with a primary focus on the US. Apeiron's efforts span direct investments in innovative companies, as well as anchor LP investments combined with minority GP stakes in emerging asset managers. Asset managers Apeiron has stakes in currently manage approximately $5 billion in external capital. Through its proprietary balance sheet, Apeiron's direct investment approach encompasses the entire company lifecycle—from incubating and accelerating breakthrough ideas to scaling growth-stage businesses as well as making impactful investments in listed companies. About Super Copper Corp. Super Copper is a mining exploration company focused on the acquisition, exploration and development of copper and precious metal projects. It is currently developing its joint venture in a prospective Chilean copper property located within the copper-rich Venado Formation in the province of Atacama, Northern Chile, a region with world-class infrastructure and the presence of global majors. | (1) These results were disclosed in the Company's news release dated February 18, 2025 titled "Super Copper Returns Multiple High-Grade Copper Assays, up to 10.3% Cu". The Company notes that grab samples are selected samples and may not represent true underlying mineralization. The technical content of this news release has been reviewed and approved by Michael Dufresne, an independent qualified person (QP) as defined by National Instrument 43-101. The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Super Copper Corp. Forward-looking statements include, but are not limited to: the terms of Apeiron's investment; the use of proceeds from the Financing; the number of RSUs granted to Aperion and the terms thereof; the Company and Apeiron entering into an investor rights agreement and the terms thereof; the timing of closing of the Financing; the directors and officers entering into voluntary lock-ups; Apeiron and the Company forming a long-term partnership; exploration activities and expansion plans at the Cordillera Cobre project, including development of Phase 2 exploration; the Cordillera Cobre project being poised for development; the Company providing a subsequent update on the Phase 2 program; the pursuit of strategic acquisitions ; and the Company's broader growth strategy. Forward-looking statements reflect management's beliefs, expectations, and estimates as of the date of this news release. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to: exploration results not meeting expectations; geological interpretations proving incorrect; difficulties in obtaining permits or financing for further exploration; changes in commodity prices and market conditions; and general economic and regulatory factors affecting the mining industry. The words "anticipate," "believe," "expect," "intend," "estimate," "plan," "may," "will," "should," "potential," and similar expressions are intended to identify forward-looking statements. Although Super Copper believes that the expectations and assumptions reflected in these statements are reasonable, no assurance can be given that actual results will be consistent with these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Investors should carefully review the risks and uncertainties described in the Company's public filings before making investment decisions. SOURCE Super Copper Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
